ALT Investors Have the Opportunity to Lead the Altimmune Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. following a significant decline in its stock price after disappointing trial results for Pemvidutide, urging affected investors to consider their legal options [2][4][5]. Group 1: Company Overview - Altimmune, Inc. is a biopharmaceutical company whose stock is traded on NASDAQ under the ticker symbol ALT [2]. - The company recently announced topline results from the IMPACT Phase 2b MASH trial, which did not meet statistical significance for its primary endpoint [4]. Group 2: Legal Actions and Investor Impact - A federal securities class action has been filed against Altimmune, with a deadline of October 6, 2025, for investors to seek the role of lead plaintiff [2][6]. - Following the announcement of the trial results, Altimmune's stock price plummeted from $7.71 per share to $3.61 per share, marking a decline of 53.2% in one day [5]. - The firm encourages any individuals with information regarding Altimmune's conduct to come forward, including whistleblowers and former employees [7].